Clin2
NCT04764331Possibly a fitRecruiting

Red light cap for scar-forming hair loss in women

Central Centrifugal Cicatricial Alopecia

Part of Skin clinical trials.

This pilot study tests an “all LED” red light cap to treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss. If you’re a woman with confirmed CCCA at Stage II–III and stable treatment, the study may help see whether red light can improve your hair loss without changing your current plan.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
5 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be a woman (18 years or older)
  • Have a confirmed CCCA diagnosis based on a skin biopsy, Stage II or III
  • Have had stable hair-loss treatment for at least 3 months (no dose/type changes)
  • Examples of stable treatments may include doxycycline, topical steroids, minoxidil, and/or injected (intralesional) steroid treatments
  • Only join if your hair loss is only CCCA (not another type) and you have not used a light source for alopecia before

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06998433Not yet recruiting· Phase 4
Platelet-rich plasma for hair loss in Black women

This trial tests whether platelet-rich plasma (PRP) injections can help treat a type of hair loss called central centrifugal cicatricial alopecia, which commonly affects Black women. PRP is made from your own blood and may help reduce inflammation and promote hair growth.

Houston, Texas
NCT07508488Recruiting· Phase 2
Deucravacitinib for scarring hair loss (Phase 2)

This study tests an oral medication called deucravacitinib for people with scarring hair loss (frontal fibrosing alopecia or central centrifugal cicatricial alopecia). It aims to see if the drug can reduce inflammation and stop or slow hair loss.

New York, New York
NCT07487948Recruiting· Phase 2
Testing the drug delgocitinib for two types of scarring hair loss

This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.

New York, New York
NCT04207931Recruiting· Phase 4
Study of treatments for a specific scar-ring hair loss

This study looks at treatment results for central centrifugal cicatricial alopecia (CCCA), a type of hair loss that causes scarring and permanent hair loss. It will follow African-American women to see how well treatments work for different levels of severity.

Winston-Salem, North Carolina
NCT07810504Recruiting
Laser and solution combo for female hair loss

This study tests a combination of a scalp solution and LED light therapy to treat androgenic alopecia (female pattern hair loss). The goal is to see if the two treatments together can help regrow hair and improve scalp health.

Pasadena, California
NCT07594678Not yet recruiting· Phase 2
Minoxidil and red-light therapy for chemotherapy hair loss

This study tests whether using minoxidil (a hair regrowth lotion) alone or with a low-level red-light therapy cap can help breast cancer patients regrow hair after chemotherapy. It aims to find a safe and effective way to improve hair regrowth after treatment.

Columbus, Ohio

Hear when a new Central Centrifugal Cicatricial Alopecia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.